Cathepsin A Mediates Ventricular Remote Remodeling and Atrial Cardiomyopathy in Rats With Ventricular Ischemia/Reperfusion.
AF, atrial fibrillation
CatA, cathepsin A
Cx43, connexin 43
ECM, extracellular matrix
I/R, ischemia/reperfusion
ICM, ischemic cardiomyopathy
LA, left atrial
LAD, left anterior descending coronary artery
LV, left ventricular
MRI, magnetic resonance imaging
PL, permanent left anterior descending ligation
SAR, (S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic-acid
atrial cardiomyopathy
atrial fibrillation
ischemia/reperfusion
mRNA, messenger ribonucleic acid
myocardial infarction
remote remodeling
Journal
JACC. Basic to translational science
ISSN: 2452-302X
Titre abrégé: JACC Basic Transl Sci
Pays: United States
ID NLM: 101677259
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
10
09
2018
revised:
08
01
2019
accepted:
11
01
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
18
7
2019
Statut:
epublish
Résumé
After myocardial infarction, remote ventricular remodeling and atrial cardiomyopathy progress despite successful revascularization. In a rat model of ventricular ischemia/reperfusion, pharmacological inhibition of the protease activity of cathepsin A initiated at the time point of reperfusion prevented extracellular matrix remodeling in the atrium and the ventricle remote from the infarcted area. This scenario was associated with preservation of more viable ventricular myocardium and the prevention of an arrhythmogenic and functional substrate for atrial fibrillation. Remote ventricular extracellular matrix remodeling and atrial cardiomyopathy may represent a promising target for pharmacological atrial fibrillation upstream therapy following myocardial infarction.
Identifiants
pubmed: 31312757
doi: 10.1016/j.jacbts.2019.01.008
pii: S2452-302X(19)30044-0
pmc: PMC6609908
doi:
Types de publication
Journal Article
Langues
eng
Pagination
332-344Références
Circulation. 1999 Jul 6;100(1):87-95
pubmed: 10393686
J Am Coll Cardiol. 1999 Jul;34(1):163-9
pubmed: 10400006
Cell Mol Life Sci. 1999 Dec;56(11-12):894-907
pubmed: 11212324
Cardiovasc Res. 2001 Nov;52(2):217-25
pubmed: 11684069
Circulation. 2003 Jun 10;107(22):2857-63
pubmed: 12771000
J Am Coll Cardiol. 2003 Jul 16;42(2):336-44
pubmed: 12875773
Circulation. 2003 Sep 23;108(12):1461-8
pubmed: 12952837
Circulation. 2004 Oct 19;110(16):2383-8
pubmed: 15477413
Eur Heart J. 2006 Dec;27(23):2866-70
pubmed: 17101637
Circulation. 2008 Apr 15;117(15):1973-81
pubmed: 18391110
Heart Fail Clin. 2010 Apr;6(2):187-200
pubmed: 20347787
J Cardiovasc Electrophysiol. 2011 Feb;22(2):175-82
pubmed: 20662987
J Cardiovasc Pharmacol. 2011 Jun;57(6):630-8
pubmed: 21150449
Circulation. 2011 Jan 18;123(2):137-46
pubmed: 21200008
Physiol Rev. 2011 Jan;91(1):265-325
pubmed: 21248168
Heart Fail Rev. 2012 May;17(3):395-409
pubmed: 21739365
J Clin Invest. 2011 Aug;121(8):2955-68
pubmed: 21804195
Circ Arrhythm Electrophysiol. 2012 Apr;5(2):380-90
pubmed: 22368123
Circulation. 2012 Mar 27;125(12):1551-62
pubmed: 22451605
J Med Chem. 2012 Sep 13;55(17):7636-49
pubmed: 22861813
Circ Arrhythm Electrophysiol. 2012 Oct;5(5):1027-35
pubmed: 22923342
Future Med Chem. 2013 Mar;5(4):399-409
pubmed: 23495688
J Transl Med. 2013 Mar 28;11:84
pubmed: 23537041
Circ Arrhythm Electrophysiol. 2013 Aug;6(4):738-45
pubmed: 23873140
J Am Coll Cardiol. 1989 Jun;13(7):1637-52
pubmed: 2656824
Cardiovasc Res. 2016 Jun 1;110(3):371-80
pubmed: 27032673
Clin Pharmacol Drug Dev. 2016 Jan;5(1):57-68
pubmed: 27119579
J Transl Med. 2016 May 31;14(1):153
pubmed: 27246731
Hypertension. 2016 Aug;68(2):385-91
pubmed: 27354423
JACC Basic Transl Sci. 2016 Jul 13;1(5):328-339
pubmed: 27642643
Matrix Biol. 2018 Aug;68-69:490-506
pubmed: 29371055
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
N Engl J Med. 1995 Dec 21;333(25):1670-6
pubmed: 7477219
Circulation. 1997 Aug 5;96(3):793-800
pubmed: 9264484
N Engl J Med. 1998 Jul 16;339(3):173-81
pubmed: 9664095
J Am Coll Cardiol. 1998 Oct;32(4):912-20
pubmed: 9768711